Literature DB >> 30032527

[Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2018 version)].

.   

Abstract

Pancreatic cancer ranks the fifth leading cause of cancer-related death, while the incidence has increased in the recent years.Although available diagnosis and treatment have failed to significantly improve patients' outcome, some advances have been made along with the understanding of the new concepts from oncology over the past several years.Pancreatic Cancer Committee of Chinese Anti-Cancer Association worked out this latest edition of "The Clinical Practice Guidelines for Pancreatic Cancer(version 2018)" based on current situation to standardize and improve the diagnosis and treatment of pancreatic cancer in China.This guideline shows algorithms for the diagnosis involving classification and staging, the systematic treatment including surgical resection, systemic chemotherapy and radiation therapy, and the whole-course management model for patients with pancreatic cancer.Different from previous consensus, this guideline contains the discussions and recommendations of 19 hot-issues in the clinical practice for pancreatic cancer in a question-oriented form, such as selection of biopsy and specimen sites, clinical diagnostic criteria for pancreatic cancer, assessment of resectable pancreatic cancer, indications and methods of preoperative biliary drainage, application of laparoscopic surgery, effect of expanding resection on patients' outcomes, dissection of group 16(th) lymph node in standard pancreaticoduodenectomy, prognostic value of serum tumor markers, and neoadjuvant therapy in patients with resectable pancreatic cancer, etc.This guideline aims to raise a better comprehensive understanding of the diagnosis and treatment of pancreatic cancer for specialists, and further improving and standardizing the clinical practice in different medical institutions.

Entities:  

Keywords:  Clinical diagnostic criteria; Combined modality therapy; Guidelines; Pancreatic neoplasms; Standardization

Mesh:

Year:  2018        PMID: 30032527     DOI: 10.3760/cma.j.issn.0529-5815.2018.07.001

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  5 in total

1.  Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist.

Authors:  Qiwen Zhang; Jingli Lu; Mengmeng Jia; Yanfang Ma; Mingyang Sun; Xiaoxu Chen; Xiaohua Ma; Yongjie Yang; Jian Kang; Xiaojian Zhang; Salvatore Paiella; Matthew H G Katz; Kunihiro Tsuchida; Mark Schattner; Shuzhang Du
Journal:  Ann Transl Med       Date:  2021-07

2.  Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.

Authors:  Liang Liang; Ying Ding; Yiyi Yu; Kai Liu; Shengxiang Rao; Yingqian Ge; Mengsu Zeng
Journal:  BMC Med Imaging       Date:  2021-04-26       Impact factor: 1.930

3.  Portal Venous Circulating Tumor Cells Undergoing Epithelial-Mesenchymal Transition Exhibit Distinct Clinical Significance in Pancreatic Ductal Adenocarcinoma.

Authors:  Yujin Pan; Deyu Li; Jiuhui Yang; Ning Wang; Erwei Xiao; Lianyuan Tao; Xiangming Ding; Peichun Sun; Dongxiao Li
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

4.  Prognostic significance of the systemic immune inflammation index in patients with metastatic and unresectable pancreatic cancer.

Authors:  Rongshuang Han; Zibin Tian; Yueping Jiang; Ge Guan; Xiaowei Wang; Xueguo Sun; Yanan Yu; Xue Jing
Journal:  Front Surg       Date:  2022-08-30

5.  Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective study.

Authors:  Ankang Wang; Bo Sun; Min Wang; Hao Shi; Zhiwei Huang; Tao He; Qiu Li; Jiaqi Deng; Wenguang Fu; Yu Jiang
Journal:  PeerJ       Date:  2020-03-18       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.